We analysed p-ERK1/2 and EdU incorporation using high-content microscopy26,27 in NCI-H358 cells (KRASG12C-mutant lung adenocarcinoma cells) treated with Dabrafenib, a clinically approved RAFi (Fig. 1A). This evidence concerns the gene MAPK3 and lung adenocarcinoma.